with three facilities in philadelphia, pa, lannett company, inc. manufactures and distributes high quality affordable generic medications that are the therapeutic equivalent of the brand-name pharmaceuticals. our portfolio consists of numerous products across a wide range of therapeutic areas. we believe that our ability to select viable products for development, efficiently develop such products, including obtaining any applicable regulatory approvals, vertically integrate ourselves into certain specialty markets and achieve economies in production are all critical for our success in the generic pharmaceutical industry in which we operate. having cultivated strong and dependable customer relationships by maintaining adequate inventory levels and demonstrating a responsive order filling system, we take pride in our ability to satisfy our customer’s needs. our dedicated employees strive to position lannett as an industry leader that is focused on quality and integrity, as well as giving
Company profile
Ticker
LCINQ, LCINQ
Exchange
Website
CEO
Timothy Crew
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NETHERLANDS SECURITIES INC
SEC CIK
Corporate docs
Subsidiaries
Cody Laboratories, Inc. • Silarx Pharmaceuticals, Inc. • Kremers Urban Pharmaceuticals, Inc. ...
IRS number
230787699
LCINQ stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
26 Jun 23
EFFECT
Notice of effectiveness
26 Jun 23
EFFECT
Notice of effectiveness
26 Jun 23
EFFECT
Notice of effectiveness
26 Jun 23
EFFECT
Notice of effectiveness
26 Jun 23
EFFECT
Notice of effectiveness
26 Jun 23
EFFECT
Notice of effectiveness
26 Jun 23
EFFECT
Notice of effectiveness
26 Jun 23
15-12G
Securities registration termination
20 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Jun 23
Transcripts
LCINQ
Earnings call transcript
2023 Q2
1 Feb 23
LCINQ
Earnings call transcript
2023 Q1
2 Nov 22
LCINQ
Earnings call transcript
2022 Q4
25 Aug 22
LCINQ
Earnings call transcript
2022 Q3
5 May 22
LCINQ
Earnings call transcript
2022 Q2
4 Feb 22
LCINQ
Earnings call transcript
2022 Q1
4 Nov 21
LCINQ
Earnings call transcript
2021 Q4
26 Aug 21
LCINQ
Earnings call transcript
2021 Q3
6 May 21
LCINQ
Earnings call transcript
2021 Q2
4 Feb 21
LCINQ
Earnings call transcript
2021 Q1
4 Nov 20
Latest ownership filings
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 22 | Jun 21 | Jun 20 | Jun 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 51.54 mm | 51.54 mm | 51.54 mm | 51.54 mm | 51.54 mm | 51.54 mm |
Cash burn (monthly) | 3.10 mm | 4.96 mm | 33.81 mm | 21.54 mm | 2.64 mm | 4.79 mm |
Cash used (since last report) | 53.55 mm | 85.65 mm | 583.45 mm | 371.71 mm | 45.55 mm | 82.62 mm |
Cash remaining | -2.01 mm | -34.11 mm | -531.91 mm | -320.17 mm | 5.99 mm | -31.08 mm |
Runway (months of cash) | -0.6 | -6.9 | -15.7 | -14.9 | 2.3 | -6.5 |
Institutional ownership, Q2 2024
46.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 31.06 mm |
Total shares | 4.97 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
MintBroker International | 3.08 mm | $18.76 mm |
D. E. Shaw & Co | 1.89 mm | $12.30 mm |
Proequities | 0.00 | $0.00 |